Verastem Inc reports results for the quarter ended December 31 - Earnings Summary
20/03/2025 20:12
Verastem Inc VSTM.OQ reported a quarterly adjusted loss of $1.33 per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of $-1.02. The mean expectation of eight analysts for the quarter was for a loss of 81 cents per share. Wall Street expected results to range from -98 cents to -68 cents per share. Reported revenue was zero; analysts expected $150.00 thousand. Verastem Inc's reported EPS for the quarter was a loss of $1.33. The company reported a quarterly loss of $64.55 million. Verastem Inc shares had risen by 35.0% this quarter. FORECAST CHANGES The mean earnings estimate of analysts had fallen by about 2.8% in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for Verastem Inc is $13.00 This summary was machine generated from LSEG data March 20 at 08:12 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Dec. 31 2024 | -0.81 | -1.33 | Missed |
| Sep. 30 2024 | -0.74 | -0.60 | Beat |
| Jun. 30 2024 | -0.95 | -0.31 | Beat |
| Mar. 31 2024 | -1.00 | -1.26 | Missed |